Lawsuits filed against businesses selling compounded injectables for diabetes and weight-loss
Novo Nordisk and Eli Lilly, who developed and won FDA approval for their blockbuster weight-loss and diabetes medicines, Ozempic, Wegovy, Mounjaro and Zepbound, have been suing businesses who they say are marketing compounded versions of these drugs with false claims.
These medical spas, wellness clinics and compounding pharmacies are allegedly violating the Lanham Act by using Novo's and Lilly's trademarks and research to persuade patients that their compounded semaglutide and tirzepatide products are equivalent to products manufactured inside the commercial supply chain.
The pink states are those where Novo Nordisk and Eli Lilly have filed lawsuits.
This is an intellectual property dispute, but it's also a patient safety issue:
- Novo and Lilly, the only FDA-approved sources for semaglutide and tirzepatide, have said that they are not supplying compounders, which leaves open questions about what IS in their products.
- The FDA has warned about reports of adverse events from compounded semaglutide, and has found that some bootleg products contain ingredients that haven't been found to be safe or effective.
- Both companies have reported finding contaminated, counterfeit and subpotent compounded versions of their products.
More on diabetes & weight-loss injectables
- Counterfeits and compounding
- Compounding lawsuits
- What it means that the shortage of weight loss drugs is almost over
More about compounded medicine
Download PSM's guides:
| Compounding harm
|
| Weight-loss injectables
|
